Abstract Library

#4524 SIRT7 drives the radioresistance of pancreatic neuroendocrine tumours via the DNMT1-MEN1 axis

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are a rare and highly heterogeneous type of tumour in the pancreas. After failure of standard treatment, patients have poor prognoses. Radiotherapy may be a potential therapeutic modality for such patients. However, PanNETs usually exhibit a radiation “cold” tumour through unclarified mechanisms.

Conference:

Presenting Author: Jianyun J

Authors: Jiang J, Xu J, Liang Y, Chen L, Ji S,

Keywords: pancreatic neuroendocrine tumour, radio resistance, SIRT7, MEN1,

#4378 Hypoxic signalling in pancreatic NETs (pNETs)

Introduction: In a genomic profiling study conducted as part of the COMPOSE Phase III multicentre open-labelled clinical trial we assessed 9 pNET patients, 2 of which showed upregulation of CA9 and hypoxic signalling. Hypoxic tumour cells present CA9 for extracellular proton channelling, maintenance of intracellular pH and to acidify and thereby vascularise and immune-suppress the TME. In normoxia, EGLN1-3 hydroxylate proline residues of HIF1A for its subsequent ubiquitination by the VHL-complex resulting in degradation and repression of its target genes.

Conference:

Presenting Author: Walter T

Authors: Walter T, Smutna V, Srirajaskanthan R, Capdevila J, Qin Y,

Keywords: hypoxia, pNET, HIF1A, CA9, Case study, hypoxic, genomic profiling,

#4150 Uncovering the role of netrins and DCC (deleted in colorectal cancer) in pancreatic neuroendocrine neoplasms (PNEN) tumorigenesis

Introduction: DCC functions as a tumor suppressor and is altered in various tumors, including neuroendocrine neoplasms. Netrin (NTN)-1 serves as the primary ligand for DCC. Operating as a dependence receptor, DCC induces apoptosis without NTN and promotes cell survival in its presence. In some cancers like small cell lung cancer and neuroblastoma, upregulation of NTN-3 rather than NTN-1 has been observed. However, the precise involvement of NTNs and DCC in PNEN remains unclear.

Conference:

Presenting Author: Sela Peremen L

Authors: Sela Peremen L, Telerman A, Peshes Yaloz N, Tirosh A,

Keywords: neuroendocrine, netrin, pancreatic neuroendocrine tumor, dcc,

#3714 CT derived body composition index analysis in metastatic NET patients treated with mTOR inhibitor

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms frequently characterized by an upregulation of the mammalian rapamycin targeting (mTOR) pathway resulting in uncontrolled cell proliferation. The mTOR pathway is also involved in skeletal muscle protein synthesis and in adipose tissue metabolism. Everolimus inhibits the mTOR pathway, resulting in blockade of cell growth and tumor progression.

Conference:

Presenting Author: Fatima A

Authors: Fatima A,

Keywords: mTOR, metastatic NET, body composition index, skeletal muscle protein,

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,